European regulators recommend Revolution Medicines' Rasonque for pancreatic cancer
- Following FDA approval, European regulators have recommended approval of Revolution Medicines' Rasonque (daraxonrasib) for pancreatic cancer, per STAT+.
- The recommendation moves the RAS(ON) inhibitor toward a second major market.
- This summary rests on the article's teaser; a separate search could not confirm the EU opinion.
💡 Points
If confirmed, a quick EU follow-on after the US nod shows how fast an oral RAS(ON) inhibitor with a clear survival benefit in a deadly cancer can move. For analysts the questions now shift to pricing, reimbursement and label expansion beyond second-line pancreatic disease. It also validates the tri-complex approach for peers still chasing KRAS in the same tumor type.
STAT+: RevMed's pancreatic cancer drug nears European approval ↗